title: [Ophtalmology].
abstract: 2013 has been the year of publications of large multicentric studies defining the modalities of different anti-VEGF and corticoid implants for the treatment of retinal diseases. The real innovation has been the growing use of iPS cells in the field of ophthalmology opening new hopes for the treatment of incurable blinding diseases.
authors.affiliation: Hôpital Ophtalmique Jules-Gonin Fondation Asile des Aveugles, Lausanne. francine.beharcohen@fa2.ch
authors.forename: Francine
authors.initials: F
authors.lastname: Behar-Cohen
mesh_terms: D000906:Antibodies / Q000008:administration & dosage / Q000009:adverse effects; D005128:Eye Diseases / Q000628:therapy; D006801:Humans; D009885:Ophthalmology / Q000379:methods / Q000639:trends*; D039904:Pluripotent Stem Cells / Q000502:physiology / Q000637:transplantation; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000276:immunology*
chemical_list: D000906:Antibodies; D042461:Vascular Endothelial Growth Factor A
vernacular_title: Ophtalmologie.